Advertisement

Journal of Neurology

, Volume 262, Issue 4, pp 823–830 | Cite as

Long-term outcome of 424 childhood-onset myasthenia gravis patients

  • Mengcui Gui
  • Xuan Luo
  • Jing Lin
  • Yue Li
  • Min Zhang
  • Xiaofan Zhang
  • Mingshan Yang
  • Wei Wang
  • Bitao Bu
Original Communication

Abstract

The objective of this study was to describe the clinical characteristics, outcome and factors that may affect the outcome of childhood-onset myasthenia gravis (CMG) patients in China. We have followed up 424 patients with CMG for at least 5 years at Tongji Hospital. At the end of follow-up, the outcome of all the patients was measured according to MGFA Post-intervention Status. In this study, the patients have been followed up for 9.8 ± 5.4 years. The mean onset age was 5.4 ± 3.6 years. Ocular myasthenia gravis (OMG) was the major type of CMG within 2 years after onset (95 %). Thymic hyperplasia was found in 116 patients, and thymoma was confirmed in 6 patients. Acetylcholine receptor antibodies were elevated in 69.5 % of the patients. All the patients were routinely treated. Thymectomy was performed in 34 patients (8.0 %). At the end of follow-up, seventy-one patients (16.7 %) were significantly improved, 66 patients (15.6 %) remained unchanged, 53 patients (12.5 %) were worsened, and 234 patients (55.2 %) were exacerbated. Importantly, fifty OMG patients (12.4 %) had transformed into generalized myasthenia gravis (GMG) over 2 years after onset. Thymectomy did not effectively reduce the transformation from OMG to GMG. However, GMG cases significantly benefited from the surgery. This study indicated that the cases with autoimmune CMG account for over 50 % in Chinese MG population. The long-term follow-up discloses that CMG patients have a low percentage of improvement, and a high percentage of worsening and exacerbation. The treatment should not be withdrawn too early after the patients obtain complete stable remission. More studies are needed to gain better control of CMG symptoms.

Keywords

Childhood-onset myasthenia gravis Ocular myasthenia gravis Transformed generalized myasthenia gravis Thymus Long-term outcome 

Notes

Acknowledgments

We thank Dr. Minhong Sun for her assistance in statistical work. The research was partly supported by a grant from Natural Science Foundation of China (No. 81271320 to Dr. Bu).

Conflicts of interest

All the authors declare no potential conflicts of interest, including relevant financial interests, activities, and relationships.

Ethical standard

The Bu Bitao's study concerning the client's right to privacy. The study was approved by the Ethical Commitee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology and was conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from the subject, and his study considered Declaration of Helsinki as a statement of ethical principles.

References

  1. 1.
    Phillips LN, Torner JC, Anderson MS, Cox GM (1992) The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42:1888–1893CrossRefPubMedGoogle Scholar
  2. 2.
    Huang X, Liu WB, Men LN, Feng HY, Li Y, Luo CM, Qiu L (2013) Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci 34:911–917CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W, Vincent A (2007) Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 78:386–390PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Wang W, Chen YP, Wang ZK, Wei DN, Yin L (2013) A cohort study on myasthenia gravis patients in China. Neurol Sci 34:1759–1764CrossRefPubMedGoogle Scholar
  5. 5.
    Ashraf VV, Taly AB, Veerendrakumar M, Rao S (2006) Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand 114:119–123CrossRefPubMedGoogle Scholar
  6. 6.
    Bever CJ, Aquino AV, Penn AS, Lovelace RE, Rowland LP (1983) Prognosis of ocular myasthenia. Ann Neurol 14:516–519CrossRefPubMedGoogle Scholar
  7. 7.
    Kupersmith MJ, Latkany R, Homel P (2003) Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60:243–248CrossRefPubMedGoogle Scholar
  8. 8.
    Oosterhuis HJ (1989) The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 52:1121–1127PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Huze C, Bauche S, Richard P et al (2009) Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 85:155–167PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Maselli RA, Ng JJ, Anderson JA et al (2009) Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet 46:203–208PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Selcen D, Juel VC, Hobson-Webb LD et al (2011) Myasthenic syndrome caused by plectinopathy. Neurology 76:327–336PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Busch C, Machens A, Pichlmeier U, Emskotter T, Izbicki JR (1996) Long-term outcome and quality of life after thymectomy for myasthenia gravis. Ann Surg 224:225–232PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Jaretzki AR, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23CrossRefPubMedGoogle Scholar
  14. 14.
    Wong SH, Huda S, Vincent A, Plant GT (2014) Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep. doi: 10.1007/s11910-013-0421-9 PubMedGoogle Scholar
  15. 15.
    Liew WK, Kang PB (2013) Update on juvenile myasthenia gravis. Curr Opin Pediatr 25:694–700CrossRefPubMedGoogle Scholar
  16. 16.
    Melbourne CR, Forrester S, Gray R, Tapper J, Trotman H (2012) Myasthenia gravis in Jamaican children: a 12-year institutional review. Paediatr Int Child Health 32:47–50CrossRefGoogle Scholar
  17. 17.
    Bu B, Yang M, Xu J, Gong F, Jiang X, Nie X (1999) The clinical study and HLA genotyping of 112 familial myasthenia gravis patients. J Tongji Med Univ 19:46–49CrossRefPubMedGoogle Scholar
  18. 18.
    Fekih-Mrissa N, Klai S, Zaouali J, Gritli N, Mrissa R (2013) Association of HLA-DR/DQ polymorphism with myasthenia gravis in Tunisian patients. Clin Neurol Neurosurg 115:32–36CrossRefPubMedGoogle Scholar
  19. 19.
    Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, Soda M, Nomura Y, Segawa M (1990) HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 86:392–399PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Luchanok U, Kaminski HJ (2008) Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 21:8–15CrossRefPubMedGoogle Scholar
  21. 21.
    Kalb B, Matell G, Pirskanen R, Lambe M (2002) Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology 21:221–225CrossRefPubMedGoogle Scholar
  22. 22.
    Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC (2012) Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 367:904–912PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Wang SJ, Yang YH, Lin YT, Yang CM, Chiang BL (2002) Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. Clin Rheumatol 21:363–368CrossRefPubMedGoogle Scholar
  24. 24.
    Ionita CM, Acsadi G (2013) Management of juvenile myasthenia gravis. Pediatr Neurol 48:95–104CrossRefPubMedGoogle Scholar
  25. 25.
    Raica M, Cimpean AM, Ribatti D (2008) Myasthenia gravis and the thymus gland. A historical review. Clin Exp Med 8:61–64CrossRefPubMedGoogle Scholar
  26. 26.
    Spillane J, Hayward M, Hirsch NP, Taylor C, Kullmann DM, Howard RS (2013) Thymectomy: role in the treatment of myasthenia gravis. J Neurol 260:1798–1801CrossRefPubMedGoogle Scholar
  27. 27.
    Chiang LM, Darras BT, Kang PB (2009) Juvenile myasthenia gravis. Muscle Nerve 39:423–431CrossRefPubMedGoogle Scholar
  28. 28.
    Mineo TC, Ambrogi V (2013) Outcomes after thymectomy in class I myasthenia gravis. J Thorac Cardiovasc Surg 145:1319–1324CrossRefPubMedGoogle Scholar
  29. 29.
    Liu N, Liu Q, Wu X, Liu K, Vadis Q (2014) Predictors of outcome of myasthenic crisis. Neurol Sci 35:1109–1114CrossRefGoogle Scholar
  30. 30.
    Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920CrossRefPubMedGoogle Scholar
  31. 31.
    Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67:652–659CrossRefPubMedGoogle Scholar
  32. 32.
    Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A (1993) Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 240:417–422CrossRefPubMedGoogle Scholar
  33. 33.
    Esposito S, Bosis S, Semino M, Rigante D (2014) Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis 33:1467–1475CrossRefPubMedGoogle Scholar
  34. 34.
    Panda S, Goyal V, Behari M, Singh S, Srivastava T (2004) Myasthenic crisis: a retrospective study. Neurol India 52:453–456PubMedGoogle Scholar
  35. 35.
    Pineles SL, Avery RA, Moss HE, Finkel R, Blinman T, Kaiser L, Liu GT (2010) Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol 150:453–459CrossRefPubMedGoogle Scholar
  36. 36.
    Wong V, Hawkins BR, Yu YL (1992) Myasthenia gravis in Hong Kong Chinese. 2 Paediatric disease. Acta Neurol Scand 86:68–72CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Mengcui Gui
    • 1
  • Xuan Luo
    • 1
  • Jing Lin
    • 1
  • Yue Li
    • 1
  • Min Zhang
    • 1
  • Xiaofan Zhang
    • 1
  • Mingshan Yang
    • 1
  • Wei Wang
    • 1
  • Bitao Bu
    • 1
  1. 1.Department of Neurology, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations